Carmot Therapeutics Inc. (CRMO)

Carmot Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2022	Dec 31, 2021
Net Income	-51.69	-38.83	25.37
Depreciation & Amortization	0.65	0.64	0.51
Share-Based Compensation	-	0.86	0.63
Other Operating Activities	-4.7	-0.57	-50.06
Operating Cash Flow	-55.73	-37.91	-23.56
Capital Expenditures	-1.74	-1.54	-1.1
Change in Investments	-	-88.21	8.01
Investing Cash Flow	-51.93	-89.76	6.9
Share Issuance / Repurchase	-	13.47	0.3
Debt Issued / Paid	-	-	30
Other Financing Activities	149.62	116.85	-
Financing Cash Flow	149.62	130.32	30.3
Net Cash Flow	41.96	2.65	13.64
Free Cash Flow	-57.47	-39.45	-24.66

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).